Molecular Imaging Biomarkers for Oncology Clinical Trials

被引：55
|
作者：
Mankoff, David A. [1 ]
Pryma, Daniel A. [1 ]
Clark, Amy S. [2 ]
机构：
[1] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2014年 / 55卷 / 04期
关键词：
cancer biomarkers; clinical trials; cancer therapy; BREAST-CANCER; FDG-PET; TRASTUZUMAB; CRITERIA;
D O I：
10.2967/jnumed.113.126128
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Biomarkers can be used to characterize disease status or predict disease behavior. Cancer biomarkers have typically relied on assays of blood or tissue; however, molecular imaging has a promising and complementary role as a cancer biomarker. This "Focus on Molecular Imaging" article reviews the current role of biomarkers to direct cancer clinical trials and clinical practice, along with current and future cancer biomarker applications of molecular imaging.
引用
收藏
页码：525 / 528
页数：4
相关论文
共 50 条
  • [1] MR Imaging Biomarkers in Oncology Clinical Trials
    Abramson, Richard G.
    Arlinghaus, Lori R.
    Dula, Adrienne N.
    Quarles, C. Chad
    Stokes, Ashley M.
    Weis, Jared A.
    Whisenant, Jennifer G.
    Chekmenev, Eduard Y.
    Zhukov, Igor
    Williams, Jason M.
    Yankeelov, Thomas E.
    MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA, 2016, 24 (01) : 11 - +
  • [2] Molecular imaging in clinical trials
    Josephs, Debra
    Spicer, James
    O'Doherty, Michael
    TARGETED ONCOLOGY, 2009, 4 (03) : 151 - 168
  • [3] Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials
    Van Heertum, Ronald L.
    Scarimbolo, Robert
    Ford, Robert
    Berdougo, Eli
    O'Neal, Michael
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 5215 - 5223
  • [4] A Review on the Use of Imaging Biomarkers in Oncology Clinical Trials: Quality Assurance Strategies for Technical Validation
    Chauvie, Stephane
    Mazzoni, Lorenzo Nicola
    O'Doherty, Jim
    TOMOGRAPHY, 2023, 9 (05) : 1876 - 1902
  • [5] Molecular imaging in clinical trials
    Debra Josephs
    James Spicer
    Michael O’Doherty
    Targeted Oncology, 2009, 4 : 151 - 168
  • [6] Promise and pitfalls of quantitative imaging in oncology clinical trials
    Kurland, Brenda F.
    Gerstner, Elizabeth R.
    Mountz, James M.
    Schwartz, Lawrence H.
    Ryan, Christopher W.
    Graham, Michael M.
    Buatti, John M.
    Fennessy, Fiona M.
    Eikman, Edward A.
    Kumar, Virendra
    Forster, Kenneth M.
    Wahl, Richard L.
    Lieberman, Frank S.
    MAGNETIC RESONANCE IMAGING, 2012, 30 (09) : 1301 - 1312
  • [7] Barriers and Facilitators to Conducting Oncology Clinical Trials in the UAE
    Al-Shamsi, Humaid O.
    CLINICS AND PRACTICE, 2022, 12 (06) : 885 - 896
  • [8] IMAGING BIOMARKERS IN CLINICAL TRIALS: WHERE IMAGING SCIENCE MEETS REGULATORS
    Hill, Derek L. G.
    2012 9TH IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI), 2012, : 908 - 908
  • [9] Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points
    Kay, A.
    Higgins, J.
    Day, A. G.
    Meyer, R. M.
    Booth, C. M.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1646 - 1651
  • [10] Using virtual clinical trials to determine the accuracy of AI-based quantitative imaging biomarkers in oncology trials using standard-of-care CT
    Byrd, Darrin
    Bontempi, Dennis
    Yang, Hao
    Aerts, Hugo
    Zhao, Binsheng
    Fedorov, Andriy
    Schwartz, Lawrence
    Allison, Tavis
    Moscowitz, Chaya
    Kinahan, Paul
    MEDICAL IMAGING 2022: IMAGE PERCEPTION, OBSERVER PERFORMANCE, AND TECHNOLOGY ASSESSMENT, 2022, 12035
12345